Lewis J. Rubin, M.D., Emeritus Professor, University of California, San Diego and Senior Advisor on SERAPHIN commented: “With this well-designed PAH study, Actelion pursued an ambitious goal to focus on outcome benefits as the primary endpoint. The impressive results of this landmark study are setting a new standard in how to conduct studies in this devastating disease.”

For more information, please refer to www.actelion.com

La réduction planifiée se fera en fonction du développement conjoncturel et de l’endettement du canton. Si le  Conseil d’Etat adopte le projet de loi, les entreprises verront donc leur taux d’imposition baisser de 24,5 pour cent en 2007 à 18 pour cent en 2017, soit une réduction de  6,5 points ou de 27 pour cent  en 10 ans. 

 
Vous trouverez de plus amples informations en allemand sur www.steuerverwaltung.bs.ch/aktuell

La Direction de l’EuroAirport se réjouit de la signature de cet accord qui représente une avancée significative dans la coopération entre les deux pays. Cet accord donne aux entreprises suisses, installées dans le secteur suisse et dans le secteur commun de l’aéroport, un cadre de référence en matière du droit du travail qu’elles pourront alors implémenter concrètement. Grâce à cet accord, les entreprises suisses pourront poursuivre leurs activités sur la plate-forme aéroportuaire avec une meilleure sécurité juridique et contribuer ainsi au développement durable de l’aéroport.

Aujourd’hui, le site de l’Aéroport de Bâle-Mulhouse emploie plus de 6 000 personnes, ce qui en fait un des plus importants employeurs de la région. 

Pour un supplément d'informations, contactez www.euroairport.com

The Christoph Merian Foundation is the sole landowner of Dreispitz and promotes its development by granting building rights. This development aims at transforming parts of this already attractive logistics and business plot into a modern and vibrant multi-use city district with a distinct identity. It will combine business, residential and leisure areas as well as culture and shopping. In addition to the already existing 400 businesses, the potential for nearly 6'000 new jobs will be created through concentration and densification, and in addition to that, apartments will be available for some 2'500 residents.

As regards the urban development, this transformation is led by a vision created by the renowned architects Herzog & de Meuron. Since 2009 this vision is being put into practice: For an area that comprises around a tenth of the whole of Dreispitz, the former "Zollfreilager" (where in the past goods in transit were stored duty free), there already is an authoritative development plan in place. All in all 300 residences are being created in this new area now called the "KunstFreilager". An arts college as well as various institutions and players from the arts and creative industries have already taken a front seat in this development as pioneers and trendsetters and have moved to Dreispitz. Notably two projects have been instrumental in realizing the KunstFreilager: The "Dreispitzhalle", an indoor event venue, and the art-, studio- and business complex "Oslo". But besides developing infrastructure and buildings there is also much consideration for public spaces and green areas.

Find more information at: www.dreispitz.ch
 
Contact:
Christoph Merian Stiftung
Herr Felix Leuppi
St. Alban-Vorstadt 5
Postfach
4002 Basel
Tel. +41 61 226 33 16
f.leuppianti spam bot@dreispitzanti spam bot.ch

Leasing

Schild AG Liestal
Marc Löhle
Eichenweg 1
CH-4410 Liestal
Tel. 061 906 97 92
liegenschaftenanti spam bot@schildanti spam bot.ch

It is no coincidence that the signing takes place just before Art Basel Miami Beach kicks off this year to celebrate its 10th anniversary. The regular exchanges between the two cultural capitals go back to the first Art Basel Miami Beach in the year 2002. Since then, the two cities have continually intensified their relationship. For Basel-Stadt, today’s signing of the official partnership treaty is also a confirmation of MCH Group’s commitment to Miami Beach as a business location.

The cities’ extensive common interests in the cultural field are at the heart of the partnership arrangement. Furthermore, strategic cooperation will also be promoted in the economic, trade, education and research fields. The city partnership model represents a platform for lively exchanges between all actors interested in these areas.

Extension of the global network
Basel is already twinned with the State of Massachusetts and the city of Shanghai, China. Building on mutual strengths, city partnerships represent an integral part of the activities performed by the Department of Presidential Affairs that have both a direct and an indirect impact on the positive development of the cities involved. Similar to Basel, the southern US city of Miami Beach is also the site of numerous cultural events, ranging from exhibitions of classic collections and modern art to ballet performances and concerts.

The Art Basel Miami Beach show is one of the most prominent art events in the United States. With its additional thriving clusters in the fields or tourism, business development and education, Miami Beach is an inspiring partner city and a welcome addition to Basel’s global network. Miami Beach has entered into over ten of such partnerships, with Basel being the only partner city in the central European region.

For further information, please contact:
Sabine Horvath
Leiterin Aussenbeziehungen und Standortmarketing Basel-Stadt
Phone +41 (0)61 267 40 87
Mobile: +41 (0)79 623 30 14
E-mail: sabine.horvathanti spam bot@bsanti spam bot.ch

For detailed information go to www.react-basel.ch./ensmeyersImmobilien ⋅ ManagementPatrick NäpflinDornachersterasse 230CH-4053 BaselTel. +41 (0)58 322 88 71Fax +41 (0)58 322 88 90patrick.naepflin@smeyers.ch

“This award is testimony to the pioneering nature of the BioVersys technology which represents an exciting novel approach towards achieving new anti-bacterial therapies as well as the potential to rejuvenate older, proven, safe and inexpensive antibiotics. In a world saturated with expensive medicines, this pioneering work may help address the escalating costs of healthcare in antiinfectives
by making obsolete antibiotics relevant again.” said Dr. Seng Chin Mah, Chairman of the Board.

Dr. Peter Burckhardt, CEO of EVA and President of BioValley Business Angels Club BioBAC, comments: “We are proud of BioVersys. The award is an external validation of our efforts in coaching and financing of spin-offs who translate scientific results into business.”

BioVersys AG is a privately held biopharmaceuticals company. It is a spin-off company from the ETH Zurich located in Basel. The company focuses on the research and development of new drugs and compounds, which switch off drug resistance within bacterial pathogens and thus restore the efficacy of existing antibiotics. (www.bioversys.com)

Swiss Technology Award Switzerland’s leading technology award presents the most innovative companies and promotes the innovate power of Switzerland. Initiated by Nicholas Hayek and Branko Weiss the award can look back on a long tradition and track record: Since 1987 over 1900 projects applied and about 370 winners were awarded. (www.swiss-innovation.com/award)

Media contact:
Dr. Marc Gitzinger
E-mail: infoanti spam bot@bioversysanti spam bot.com
Tel: +41 61 633 22 50

“Our mission at Canyon Pharmaceuticals is to connect people and science to deliver life-saving medicines that serve today’s unmet needs,” notes Dawn Bell, PharmD, Senior Vice President and General Manager of Canyon’s US subsidiary.  “We worked closely with our acute-care physician and pharmacy colleagues to understand the gaps with current therapies and subsequently launched a highly differentiated anticoagulant that serves critical unmet needs in the hospitalized patient.”

“To achieve this recognition is truly gratifying and a testament to the important unmet needs in the anticoagulant marketplace that Iprivask is able to address,” says Seng Chin Mah, CEO of Canyon Pharmaceuticals Group AG.

About Canyon

Canyon PharmaceuticalsTM is a privately held specialty biopharmaceutical company focused on delivering innovative therapeutic solutions that target important cellular pathways in thrombosis, tumor growth, and metastasis. Canyon holds exclusive world-wide rights to desirudin, a subcutaneous (SC) recombinant direct thrombin inhibitor (DTI), and to pegmusirudin, a pegylated recombinant DTI with a longer duration of action than desirudin.

Media Contact:
Dr. Seng Chin Mah
E-mail: seng_chin.mahanti spam bot@canyonpharmaanti spam bot.com
Tel: +41 61 201 1383
http://www.canyonpharma.com/